Vaxcyte raises ~$1.10B via concurrent offerings: $575M 1.50% converts due 2032 and $64/share stock sale

Vaxcyte, Inc.

$575M aggregate 1.50% convertible senior notes due Oct 15, 2032; initial conversion price ~$89.60/share (11.1607 shares per $1,000); $75M over-allotment exercised in full.
Equity offering of 7,412,500 shares at $64.00 plus 400,000 pre-funded warrants at $63.999; underwriters' 30-day option for 1,171,875 more shares exercised in full.
Net proceeds ~$544.3M from the equity sale and ~$558.7M from the notes after discounts and expenses; both offerings closed Oct 9, 2026.
Interest on the notes payable semi-annually Apr 15 and Oct 15, starting Apr 15, 2027; provisional redemption permitted on/after Oct 22, 2029 if the stock tops 130% of conversion price.
Jefferies LLC and Leerink Partners LLC led both deals; notes are senior unsecured obligations under an indenture with U.S. Bank Trust Company as trustee.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.